23andMe Appoints Angela Wonson Vice President of Communications
June 20, 20147
Health Care Communications Industry Veteran Joins 23andMe Leadership Team
Mountain View, Calif. – June 20, 20147 – 23andMe, the leading personal genetics company, today announced the appointment of Angela Wonson as vice president, communications. Wonson brings more than 18 years of communications expertise in the health care, science and technology industries to 23andMe.
She will oversee the company’s corporate communications, media relations, investor relations and internal communications activities.
“Angela’s experience working across a diverse group of medical device, patient advocacy, technology and consumer health brands is a great addition to our leadership team,” said Andy Page, President of 23andMe.
Prior to joining 23andMe, Wonson served as vice president of communications and senior media advisor at Intuitive Surgical ($ISRG), the global leader in robotic-assisted surgery. Prior to joining Intuitive Surgical, Wonson held senior positions in health care media relations at both Weber Shandwick and Edelman Public Relations. She also served as the chief communications officer at The Cleveland Clinic.
Wonson began her career in television working in a number of roles including production, community affairs, news, and later in corporate communications for MSNBC and CNBC.
“23andMe is shaping the future of how genetic information can be used at both the individual and societal level,” said Wonson. “I am thrilled to be part of the team supporting this effort.”
Wonson holds a Master of Public Administration from the John F. Kennedy School of Government, Harvard University and a Bachelor of Arts in Communications from the University of California, San Diego.
23andMe, Inc., headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA clearances for genetic health reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80% of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. More information is available at www.23andMe.com.